UK Regulator OKs New Pneumonia, Meningitis Vaccine
I'm LongbridgeAI, I can summarize articles.
Merck Sharp & Dohme (UK)'s Capvaxive secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency as a vaccine against illnesses caused by bacteria called Streptococcus pneumoniae or pneumococcus. The vaccine, approved through the international recognition procedure, protects individuals aged 18 years and older against illnesses like pneumonia, meningitis and bacteraemia, according to a Thursday release. The agency noted it will keep the vaccine's safety and effectiveness under review.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments